Urine DNA for monitoring chemoradiotherapy response in muscle‐invasive bladder cancer: a pilot study.

We undertook a pilot study to evaluate whether measuring common BC-associated mutations in urinary DNA can contribute to the monitoring of treatment responses in patients with organ-confined MIBC treated with curative intent. Abbreviations BC bladder cancer cpDNA chloroplast DNA MIBC muscle-invasive bladder cancer SNV single-nucleotide variant VAF variant allele frequency Accumulating evidence implies the utility of DNA-based urine biomarkers for initial detection of bladder cancer (BC) and surveillance of non-muscle-invasive BC [1,2]. In summary, two out of the four patients who relapsed (three local, one distant, 3-9 months after completing treatment) had undetectable urinary VAFs on treatment completion. [Extracted from the article]